EMA Expands Early Engagement With Patients & Health Professionals
On the back of a successful pilot of early consultations with patients, the European Medicines Agency is extending the initiative so that patient and health care professional groups can give valuable input in areas such as unmet needs, clinical trial endpoints and expectations for future treatments.
You may also be interested in...
A 17-month pilot by the European Medicines Agency has highlighted the benefits of obtaining the views of patients much earlier on in the review of marketing authorization applications for orphan drugs.
New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.
The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.